Ibogaine Opioid Treatment Research: What 2025-2026 Studies Found
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal...
Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
MDMA Therapy FDA Decision, What the Rejection Letter Means for Seekers
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time,...
RFK Jr. and Psychedelic Therapy: What Seekers Should Know
RFK Jr. psychedelic therapy support has brought real political attention to substances like psilocybin, MDMA, and ibogaine. For seekers already exploring this space, the shift matters....
Psychedelic Therapy for Veterans: What the Research Shows
Psychedelic therapy for veterans is one of the most actively researched areas in mental health today. Clinical trials involving MDMA and psilocybin have shown meaningful reductions...
Ibogaine Treatment Texas: Veterans, $50M, and What Comes Next
Texas has committed $50 million to fund clinical trials for ibogaine treatment Texas programs focused on veterans and first responders. The research is early and the...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.